Details
Description
Inclusion Criteria
Exclusion Criteria
Details
Title The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (ARRAY BioPharma Inc.)
IRB ARRY162311
CC 13-1209
Hospital Fairview, Hillcrest, Main Campus
Stage Recurrent/Relapsed
Phase Phase 3
Disease Fallopian Tube, Gynecologic, Ovarian, Peritoneal
